Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple claims are not supported by the provided FDA label excerpts (notably cardiovascular disease indication/benefit and pancreatitis incidence estimates/boxed warning), and there is at least one clear contradiction regarding pancreatitis risk/label limitation. Several safety-adjacent claims lack label support in the provided text.
Category Scores
Accurate Statements
Icosapent is an omega-3 fatty acid medication derived from the oil of the fish mackerel.
Label description states it is an ethyl ester of EPA obtained from oil of fish (Section 11/Description) but does not specify mackerel.
Icosapent reduces triglyceride levels in the blood.
Dose-ranging and TG outcomes described; indication is to reduce TG levels (Sections 1 and 12.1/14.2).
Inhibiting production of triglycerides in the liver is a mechanism by which icosapent reduces blood triglycerides.
Label mechanism: studies suggest EPA reduces hepatic VLDL-TG synthesis and/or secretion and enhances TG clearance (Section 12.1).
Pancreatitis has been reported with icosapent use.
Provided label excerpt includes a limitation: effect on risk for pancreatitis has not been determined (Section 1). The excerpt does not state pancreatitis has been reported.
Allergic reactions, including anaphylaxis, have been reported in some patients taking icosapent.
Label excerpt includes hypersensitivity/anaphylactic reaction in contraindications and fish allergy guidance (Sections 4 and 5.2), but does not state incidence or that anaphylaxis has been reported.
Icosapent may increase the risk of bleeding.
Label: increased risk of bleeding (Section 5.3) and monitor with concomitant anticoagulants/antiplatelet agents (Section 7.1).
The bleeding risk with icosapent may be particularly increased in patients taking anticoagulant medications.
Label states incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin (Section 5.3) and advises monitoring with concomitant anticoagulants/antiplatelet agents (Section 7.1).
Patients taking icosapent should be monitored for signs of pancreatitis, including abdominal pain, nausea, and vomiting.
Provided label excerpt does not describe pancreatitis monitoring or symptom specifics.
Patients taking icosapent should be closely monitored for signs of pancreatitis and other severe side effects.
Provided label excerpt does not describe pancreatitis symptom monitoring.
Unsupported Statements
Icosapent (VASCEPA) is a prescription medication used to treat patients with high triglycerides and cardiovascular disease.
Provided label excerpt (Section 1) indicates use to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia as an adjunct to diet; cardiovascular disease indication/approval is not stated in the provided text.
Icosapent is an omega-3 fatty acid medication derived from the oil of the fish mackerel.
Label excerpt says obtained from oil of fish but does not specify mackerel (Section 11/Description).
In the REDUCE-IT trial, icosapent reduced the risk of major adverse cardiovascular events (MACE) by 25% compared with placebo.
No REDUCE-IT trial or MACE 25% reduction is present in the provided label excerpts (Sections 1, 5, 14 excerpts provided).
The most common side effects of icosapent include nausea, vomiting, and diarrhea.
Provided label adverse reactions excerpt does not list nausea/vomiting/diarrhea; common adverse reactions listed are musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation (Section 6).
Pancreatitis has been reported with icosapent use.
Provided label excerpt only states the effect on pancreatitis risk has not been determined; it does not report pancreatitis occurrence (Section 1).
The incidence of pancreatitis associated with icosapent use is estimated to be around 0.1% to 0.2%.
No pancreatitis incidence estimate is provided in the supplied label excerpts.
The incidence of pancreatitis associated with icosapent use is estimated to be around 0.3% to 0.5%.
No pancreatitis incidence estimate is provided in the supplied label excerpts.
DrugPatentWatch.com states that icosapent has a boxed warning for pancreatitis.
The provided FDA label excerpts do not include any boxed warning text; also the statement relies on an external non-label source.
Patients taking icosapent should be monitored for signs of pancreatitis, including abdominal pain, nausea, and vomiting.
No pancreatitis monitoring instructions or symptom list are present in the supplied label excerpts.
Patients taking icosapent should be closely monitored for signs of pancreatitis and other severe side effects.
Provided label excerpts do not describe monitoring for pancreatitis signs/symptoms.
Contradictions
Low
AI Statement
Pancreatitis has been reported with icosapent use.
Label Reference
Section 1 limitation: “The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.”
Low
AI Statement
DrugPatentWatch.com states that icosapent has a boxed warning for pancreatitis.
Label Reference
Provided label excerpts do not show a boxed warning for pancreatitis; Section 1 instead states effect on pancreatitis risk has not been determined.
Important Omissions
Indication is specifically as an adjunct to diet to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia, and the label limitation states the effect on pancreatitis risk has not been determined.
Importance:
High
Dose and administration instructions (4 g/day taken as two/two or four/twice daily with food; swallow whole; do not break open/crush/dissolve/chew).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims introduce unsupported pancreatitis specifics (reported incidence, boxed warning assertion, and symptom monitoring) and a cardiovascular disease benefit/indication not present in the provided label excerpts, which could mislead prescribing decisions. Bleeding risk with antithrombotics is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Cardiovascular disease/MACE claims and pancreatitis/boxed warning/monitoring details are not supported by the provided FDA label excerpts and include statements that conflict with the label limitation that pancreatitis risk effect has not been determined.
Suggested Improvement
Restrict statements to the provided label: adjunct-to-diet TG reduction in adults with severe (≥500 mg/dL) hypertriglyceridemia; include label-supported mechanisms and bleeding precautions; avoid pancreatitis incidence/boxed warning/REDUCE-IT MACE quantification unless present in the label text; avoid specifying fish species and avoid listing common adverse reactions not listed in Section 6.